Top Page
Vitalhub
(TSX:VHI)
Vitalhub (VHI) vs. iShares MSCI Canada ETF (EWC)
Vitalhub Business Overview & Revenue Model
Vitalhub Earnings Call Summary
Vitalhub Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 82.63M | 68.59M | 52.51M | 39.97M | 24.66M | 13.79M |
| Gross Profit | 66.85M | 55.49M | 42.81M | 32.94M | 19.43M | 10.29M |
| EBITDA | 13.66M | 11.90M | 10.38M | 5.25M | 1.12M | 148.12K |
| Net Income | 4.95M | 3.00M | 4.55M | 1.21M | -1.95M | -2.17M |
Balance Sheet | ||||||
| Total Assets | 277.26M | 207.19M | 118.78M | 106.19M | 72.77M | 64.08M |
| Cash, Cash Equivalents and Short-Term Investments | 94.01M | 56.57M | 33.48M | 17.45M | 16.39M | 23.39M |
| Total Debt | 15.59M | 608.76K | 541.09K | 882.20K | 792.51K | 987.89K |
| Total Liabilities | 94.93M | 62.33M | 36.88M | 30.79M | 17.95M | 13.77M |
| Stockholders Equity | 182.33M | 144.86M | 81.91M | 75.40M | 54.82M | 50.31M |
Cash Flow | ||||||
| Free Cash Flow | 13.44M | 14.24M | 20.18M | 5.83M | -309.58K | 294.35K |
| Operating Cash Flow | 14.23M | 15.13M | 20.47M | 6.12M | -49.97K | 405.14K |
| Investing Cash Flow | -38.75M | -31.39M | -4.15M | -21.84M | -10.06M | -9.37M |
| Financing Cash Flow | 48.57M | 39.09M | -287.89K | 16.40M | 3.17M | 30.37M |
Vitalhub Technical Analysis
Vitalhub Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | 550.33M | 1,070.37 | 0.72% | ― | 39.32% | ― | |
55 Neutral | 11.63M | -1.96 | ― | ― | -72.12% | 40.30% | |
55 Neutral | C$687.45M | 122.20 | 3.23% | ― | 41.68% | -16.15% | |
46 Neutral | 26.99M | -5.36 | -1838.81% | ― | -47.10% | -19.32% | |
34 Underperform | 13.36M | -2.22 | ― | ― | ― | 21.61% | |
34 Underperform | 56.27M | -4.28 | ― | ― | ― | 40.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Vitalhub Corporate Events
VitalHub Corp. has announced the filing of a prospectus supplement in connection with a ‘bought deal’ public offering to distribute over 5 million common shares, aiming to raise approximately $65 million. The offering, expected to close around August 20, 2025, is subject to regulatory approval and involves co-lead underwriters Cormark Securities Inc. and National Bank Financial Inc. The move is part of VitalHub’s strategy to strengthen its market position and expand its financial resources, potentially impacting its operations and stakeholders positively.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. has announced a $65 million bought deal public offering, with Cormark Securities Inc. and National Bank Financial Inc. acting as co-lead underwriters. The proceeds from this offering will be used for growth initiatives, including future acquisitions and general corporate purposes, with the closing expected around August 20, 2025, pending regulatory approval. This strategic move is expected to bolster VitalHub’s market position and support its aggressive growth strategy, potentially impacting stakeholders by enhancing the company’s operational capabilities and expanding its market reach.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub reported significant financial growth in the second quarter of 2025, with annual recurring revenue up 55% year-over-year to $79.6 million and total revenue up 47% to $23.9 million. The company has successfully integrated its 2024 acquisitions, including Novari and Induction, enhancing its patient flow solutions and expanding its international presence. With over $40 million in cash and more than $90 million in ARR, VitalHub is well-positioned for continued expansion.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. announced it will release its Q2 2025 financial results on August 7, 2025, followed by a conference call on August 8, 2025, hosted by CEO Dan Matlow and CFO Brian Goffenberg. This announcement is part of VitalHub’s ongoing efforts to engage with stakeholders and provide transparency about its financial performance, which could impact its market positioning and stakeholder confidence.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. has announced the acquisition of Novari Health Inc., a Canadian healthcare software provider specializing in patient flow solutions, for $43.6 million with potential additional performance-based payments. This acquisition is expected to bolster VitalHub’s position in the Canadian market and facilitate global expansion, particularly in the UK, by leveraging Novari’s established technologies and VitalHub’s international presence, enhancing value for customers and stakeholders.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. announced the results of its annual general meeting, where all director nominees were elected to the board, and MNP LLP was appointed as auditors. The meeting saw a 60.45% participation rate of the total shares issued and outstanding. These developments reinforce VitalHub’s governance structure and ensure continued oversight and financial integrity, which are crucial for its ongoing growth and market positioning.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub has completed the acquisition of Induction Healthcare Group PLC, enhancing its product offerings with Induction’s software solutions like Zesty and Attend Anywhere. This acquisition, valued at approximately £9.7 million, is expected to complement VitalHub’s existing solutions, improve healthcare partner value, and enhance patient outcomes, thereby strengthening its position in the healthcare software industry.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.
VitalHub Corp. has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Alberta, British Columbia, and Ontario. This filing, once finalized, will allow the company to qualify the distribution of up to $250 million in various securities over a 25-month period. Although VitalHub has no immediate plans to offer securities under this prospectus, the move positions the company to quickly capitalize on future opportunities, potentially impacting its financial strategy and market positioning.
The most recent analyst rating on (TSE:VHI) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Vitalhub stock, see the TSE:VHI Stock Forecast page.